世界のT細胞療法市場2021-2028:モダリティ別、治療別(CAR T細胞、腫瘍浸潤リンパ球)、疾患別(血液悪性腫瘍、固形腫瘍)、地域別

◆英語タイトル:T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21MC054
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年2月26日
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界のT細胞療法市場規模が2028年までに203憶ドルに達すると予測しています。2021年から2028年までに年平均20.2%成長する見通しです。本調査レポートでは、T細胞療法の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、モダリティ別(研究、商品化)分析、治療別(CAR T細胞、T細胞受容体(TCR)ベース、腫瘍浸潤リンパ球(TIL)ベース)分析、疾患別(血液悪性腫瘍、固形腫瘍、その他)分析、地域別分析、競争状況などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・T細胞療法の世界市場規模:モダリティ別(研究、商品化)
・T細胞療法の世界市場規模:治療別(CAR T細胞、T細胞受容体(TCR)ベース、腫瘍浸潤リンパ球(TIL)ベース)
・T細胞療法の世界市場規模:疾患別(血液悪性腫瘍、固形腫瘍、その他)
・T細胞療法の世界市場規模:地域別
・競争状況
【レポートの概要】

T-cell Therapy Market Growth & Trends

The global T-cell therapy market size is expected to reach USD 20.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 20.2% from 2021 to 2028. The milestone approvals of Kymriah and Yescarta along with the recent approval of Tecartus have bolstered the exponential revenue growth in the market.

The commercial launch of these innovative therapies across various regions has spurred the investment flow in this arena thereby driving the market. Cancer indications are the major investment targets for the key operating players. However, space is constantly expanding to include other indications such as viral infections, creating lucrative opportunities for the operating players.

Engineered T-cell marketspace is characterized by an in-depth network of several entities marked by financially, academically, and licensing agreements. Collaborations between research bodies and manufacturers to assess the efficacy and safety of therapies are anticipated to put forth the advancements in the space, thereby expected to result in the anticipated success of the market.

By far, the wider application of CAR-T therapies has been hampered by the considerable lack of efficiency to treat solid tumors and linked toxicity concerns due to the strong immunosuppressive tumor microenvironment. Thus, operating players are engaged in implementing new approaches to overcome these challenges and expand the application in solid.

T-cell Therapy Market Report Highlights

• Research modality accounted for the largest revenue share with the growing pipeline of products entering clinical and pre-clinical phases

• The commercial base is expected to witness growth owing to the increasing regulatory approvals for commercial products across various countries as well as a rise in the number of medical centers implementing these therapies

• The geographical expansion of Kymriah and Yescarta in Europe and the Asia Pacific has encouraged the investors to support the development in this space

• CAR-T therapies contributed to the largest revenue share owing to the high investment flow in this therapy type

• The high number of clinical trials for CAR-T therapies further supports the dominance of the segment in the global space

• The presence of approved products such as Kymriah, Yescarta, and Tecartus for the treatment of hematological malignancies has resulted in anticipated segment growth

• The development of therapy for solid tumors has created lucrative opportunities for players to capture untapped avenues

• COVID-19 pandemic has opened new research opportunities for market players to invest in T-cell space for viral infections

• The scientific community is actively engaged in evaluating the T-cell therapy potential in COVID-19 patients thus supplementing the market growth

• North America dominated in 2020 global market owing to the exponential rise in clinical trials pertaining to T-cell therapies

• A strong commercial base in the U.S. further contributed to the dominance of the region in the market

• The shifting focus of U.S.-based companies from conventional drug development to t-cell therapies also drives regional growth

• Asia-Pacific is projected to witness the fastest CAGR with emerging markets such as China at the forefront

• China tops the list of registered clinical trials for CAR-T surpassing the U.S. More than 300 clinical trials are ongoing in China

• Key companies are undertaking various strategic initiatives to maintain their market position

• For instance, Bayer collaborated with Atara Biotherapeutics in December 2020 for the development of mesothelin-targeted CAR T-cell therapies to treat solid tumors

【レポートの目次】

Table of contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Competition Milieu
2.2 Market Snapshot
2.3 Segment Outlook
Chapter 3 Market Variables, Trends, & Scope
3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2020
3.2 T-Cell Therapy- Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
3.2.1.2 Growing competition among market players
3.2.1.3 Approval of Kymriah and Yescarta across various countries
3.2.1.4 Developments in CAR T-cell therapy for solid tumors
3.2.1.5 Technological advancements in manufacturing process
3.2.2 Market restraint analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.2.2.1 High prices of therapies
3.2.2.2 CAR T limitations
3.2.3 Opportunity analysis
3.2.3.1 Facility expansion for cell and gene therapies
3.2.3.1 Rising global financings in gene and cell therapy arena
3.2.3.2 Ongoing developments in viral & non-viral vector manufacturing arena
3.3 Regulatory Landscape
3.3.1 Current and potential future approvals
3.3.2 Frameworks for risk mitigation and safety monitoring
3.3.3 Regulatory framework, by geography
3.3.3.1 U.S.
3.3.3.2 Europe
3.3.3.3 China
3.3.3.4 Japan
3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
3.4.1 Insurance coverage
3.4.2 Value-based price benchmarks
3.4.3 Alternate payment strategies
3.5 Patent Landscape
3.6 Deals, Funding’s, Partnerships and Collaborations
3.6.1 Licensing deals
3.6.2 Merger & acquisition deals
3.6.3 Collaboration & partnerships
3.7 Pipeline Analysis
3.7.1 Clinical trial landscape
3.8 Geographic Mapping of Companies
3.9 Competitive Landscape for CD19­directed CAR­T Therapies and Other T-cell therapies
3.10 T-cell Therapy Market—SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.10.1 Political landscape
3.10.2 Economic landscape
3.10.3 Social landscape
3.10.4 Technology landscape
3.11 Industry Analysis – Porter’s
3.11.1 Supplier bargaining power
3.11.2 Buyer bargaining power
3.11.3 Substitution threat
3.11.4 Threat from new entrant
3.11.5 Competitive rivalry
Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis
4.1 T-cell Therapy Market: Modality Movement Analysis
4.2 Research
4.2.1 Global research-based T-cell therapy market, 2017 – 2028 (USD Million)
4.3 Commercialized
4.3.1 Global commercial T-cell therapy market, 2017 – 2028 (USD Million)
Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
5.1 T-cell Therapy Market: Therapy Type Movement Analysis
5.2 CAR T-cell Therapy
5.2.1 Global CAR T-cell Therapy market, 2017 – 2028 (USD Million)
5.3 T Cell Receptor (TCR)-based
5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2017 – 2028 (USD Million)
5.4 Tumor Infiltrating Lymphocytes (TIL)-based
5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2017 – 2028 (USD Million)
Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis
6.1 T-cell Therapy Market: Indication Movement Analysis
6.2 Hematologic Malignancies
6.2.1 Global T-cell therapy market for hematologic malignancies, 2017 – 2028 (USD Million)
6.2.2 Lymphoma
6.2.2.1 Global T-cell therapy market for lymphoma, 2017 – 2028 (USD Million)
6.2.3 Leukemia
6.2.3.1 Global T-cell therapy market for leukemia, 2017 – 2028 (USD Million)
6.2.4 Myeloma
6.2.4.1 Global T-cell therapy market for myeloma, 2017 – 2028 (USD Million)
6.3 Solid Tumors
6.3.1 Global T-cell therapy market for solid tumors, 2017 – 2028 (USD Million)
6.3.2 Melanoma
6.3.2.1 Global T-cell therapy market for melanoma, 2017 – 2028 (USD Million)
6.3.3 Brain & Central Nervous System
6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2017 – 2028 (USD Million)
6.3.4 Liver cancer
6.3.4.1 Global T-cell therapy market for liver cancer, 2017 – 2028 (USD Million)
6.3.5 Others
6.3.5.1 Global T-cell therapy market for other cancer forms, 2017 – 2028 (USD Million)
6.4 Others
6.4.1 Global T-cell therapy market for others, 2017 – 2028 (USD Million)
Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Modality & Therapy Type
7.1 T-cell Therapy Market Share by Regional, 2017 & 2025
7.2 North America
7.2.1 North America T-cell therapy market, 2017 – 2028 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.2.2.2 U.S. T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.2.2.3 U.S. T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.2.3 Canada
7.2.3.1 Canada T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.2.3.2 Canada T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.2.3.3 Canada T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.3 Europe
7.3.1 Europe T-cell therapy market, 2017 – 2028 (USD Million)
7.3.2 Germany
7.3.2.1 Germany T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.3.2.2 Germany T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.3.2.3 Germany T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.3.3 U.K.
7.3.3.1 U.K. T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.3.3.2 U.K. T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.3.3.3 U.K. T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific T-cell therapy market, 2017 – 2028 (USD Million)
7.4.2 Japan
7.4.2.1 Japan T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.4.2.2 Japan T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.4.2.3 Japan T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.4.3 China
7.4.3.1 China T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.4.3.2 China T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.4.3.3 China T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.5 Latin America
7.5.1 Latin America T-cell therapy market, 2017 – 2028 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil T-cell therapy market, by modality, 2017 – 2028 (USD Million)
7.5.2.2 Brazil T-cell therapy market, by therapy type, 2017 – 2028 (USD Million)
7.5.2.3 Brazil T-cell therapy market, by indication, 2017 – 2028 (USD Million)
7.6 MEA
7.6.1 MEA T-cell therapy market, 2017 – 2028 (USD Million)
7.6.2 South Africa
7.6.2.1 Brazil T-cell therapy market, 2016 – 2026 (USD Million), by modality
7.6.2.2 Brazil T-cell therapy market, 2016 – 2026 (USD Million), by therapy type
7.6.2.3 Brazil T-cell therapy market, 2016 – 2026 (USD Million), by indication
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Company Profiles
8.2.1 Novartis AG
8.2.1.1 Company overview
8.2.1.1.1 AveXis, Inc.
8.2.1.2 Financial performance
8.2.1.3 Product benchmarking
8.2.1.4 Strategic initiatives
8.2.2 Gilead Sciences
8.2.2.1 Company overview
8.2.1.1.1 Kite Pharma
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.4 Strategic initiatives
8.2.3 bluebird bio, Inc.
8.2.3.1 Company overview
8.2.3.2 Financial performance
8.2.3.3 Product benchmarking
8.2.3.4 Strategic initiatives
8.2.4 TCR2 Therapeutics Inc
8.2.4.1 Company overview
8.2.4.2 Financial performance
8.2.4.3 Product benchmarking
8.2.4.4 Strategic initiatives
8.2.5 Sorrento Therapeutics
8.2.5.1 Company overview
8.2.5.2 Product benchmarking
8.2.5.3 Strategic initiatives
8.2.6 Fate Therapeutics
8.2.6.1 Company overview
8.2.6.2 Financial performance
8.2.6.3 Product benchmarking
8.2.6.3 Strategic initiatives
8.2.7 Merck KGaA
8.2.7.1 Company overview
8.2.7.2 Financial performance
8.2.7.3 Product benchmarking
8.2.7.3 Strategic initiatives
8.2.8 Pfizer Inc.
8.2.8.1 Company overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.4 Strategic initiatives
8.2.9 Amgen
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.4 Strategic initiatives
8.2.10 Celgene Corporation
8.2.10.1 Company overview
8.2.1.1.1 Juno Therapeutics
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.4 Strategic initiatives

List of Tables

TABLE 1 Summary of finalized, proposed, and modeled payment adjustments, 2019 - 2023
TABLE 2 Licensing deals in T-cell therapy space
TABLE 3 Merger & acquisition deals in T-cell therapy space
TABLE 4 Collaboration & partnerships in T-cell therapy space
TABLE 5 CAR T-cell target antigens in US trials
TABLE 6 CAR T-cell target antigens in China trials
TABLE 7 Competitive landscape for CD 19-directed CAR T Therapies in r/r lymphoma and leukemia
TABLE 8 CAR T-cell targets under investigation for hematologic malignancies
TABLE 9 North America T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 10 North America T-cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
TABLE 11 North America T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 12 North America T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 13 North America T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 14 U.S. T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 15 U.S. T-cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
TABLE 16 U.S. T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 17 U.S. T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 18 U.S. T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 19 Canada T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 20 Canada T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 21 Canada T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 22 Canada T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 23 Canada T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 24 Europe T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 25 Europe T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 26 Europe T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 27 Europe T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 28 Europe T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 29 Germany T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 30 Germany T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 31 Germany T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 32 Germany T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 33 Germany T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 34 U.K. T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 35 U.K. T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 36 U.K. T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 37 U.K. T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 38 U.K. T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 39 Asia Pacific T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 40 Asia Pacific T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 41 Asia Pacific T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 42 Asia Pacific T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 43 Asia Pacific T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 44 Japan T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 45 Japan T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 46 Japan T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 47 Japan T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 48 Japan T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 49 China T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 50 China T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 51 China T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 52 China T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 53 China T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 54 Latin America T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 55 Latin America T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 56 Latin America T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 57 Latin America T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 58 Latin America T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 59 Brazil T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 60 Brazil T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 61 Brazil T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 62 Brazil T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 63 Brazil T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 64 MEA T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 65 MEA T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 66 MEA T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 67 MEA T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 68 MEA T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 69 South Africa T-cell therapy market estimates & forecasts, by modality, 2017 - 2028 (USD Million)
TABLE 70 South Africa T-cell therapy market estimates & forecasts, by therapy-type, 2017 - 2028 (USD Million)
TABLE 71 South Africa T-cell therapy market estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 72 South Africa T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2017 - 2028 (USD Million)
TABLE 73 South Africa T-cell therapy market for solid tumors estimates & forecasts, by indication, 2017 - 2028 (USD Million)


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value-chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market segmentation & scope
FIG. 9 Market trends & outlook
FIG. 10 Penetration & growth prospect mapping for therapy, 2018
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Annual Investment in the CAR-T Space, 2013-2026
FIG. 13 Global financings in cell therapy, 2016-2018
FIG. 14 Partnerships of selected major companies in CAR T space
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
FIG. 17 CAR T Cell patent landscape by Derwent World Patents Index (DWPI)
FIG. 18 Major leaders in CAR T-cell therapy patent, by Derwent World Patents Index
FIG. 19 CAR T Cell patent landscape by Derwent World Patents Index (DWPI)
FIG. 20 Licensing, joint venture and research-only oncology deals by volume and value from 2014 to 2018
FIG. 21 Adoptive cellular therapy: Clinical trial landscape
FIG. 22 Ongoing projects for CAR T-cell therapies
FIG. 23 Geographic distribution of gene therapy clinical trials, 2017 & 2018
FIG. 24 SWOT analysis, by factor (Political & legal, economic, and technological)
FIG. 25 Porter’s Five Forces Analysis
FIG. 26 T-cell therapy market: Modality outlook key takeaways
FIG. 27 Global T-cell therapy market: Modality movement analysis
FIG. 28 Global research-based T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 29 Global commercial T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 30 T-cell therapy market: Therapy type outlook key takeaways
FIG. 31 Global T-cell therapy market: Therapy type movement analysis
FIG. 32 Global CAR T-cell Therapy market, 2017 - 2028 (USD Million)
FIG. 33 Global T Cell Receptor (TCR)-based therapy market, 2017 - 2028 (USD Million)
FIG. 34 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2017 - 2028 (USD Million)
FIG. 35 T-cell therapy market: Indication outlook key takeaways
FIG. 36 Global T-cell therapy market: Therapy type movement analysis
FIG. 37 Global T-cell therapy market for hematologic malignancies, 2017 - 2028 (USD Million)
FIG. 38 Global T-cell therapy market for lymphoma, 2017 - 2028 (USD Million)
FIG. 39 Global T-cell therapy market for leukemia, 2017 - 2028 (USD Million)
FIG. 40 Global T-cell therapy market for myeloma, 2017 - 2028 (USD Million)
FIG. 41 Global T-cell therapy market for solid tumors, 2017 - 2028 (USD Million)
FIG. 42 Global T-cell therapy market for melanoma, 2017 - 2028 (USD Million)
FIG. 43 Global T-cell therapy market for brain & central nervous system, 2017 - 2028 (USD Million)
FIG. 44 Global T-cell therapy market for liver cancer, 2017 - 2028 (USD Million)
FIG. 45 Global T-cell therapy market for other cancer forms, 2017 - 2028 (USD Million)
FIG. 46 Global T-cell therapy market for others, 2017 - 2028 (USD Million)
FIG. 47 Regional market place: Key takeaway
FIG. 48 T-cell therapy market regional outlook, 2017 & 2028
FIG. 49 North America T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 50 U.S. T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 51 Canada T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 52 Europe T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 53 Germany T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 54 U.K. T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 55 Asia Pacific T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 56 Japan T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 57 China T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 58 Latin America T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 59 Brazil T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 60 MEA T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 61 South Africa T-cell therapy market, 2017 - 2028 (USD Million)
FIG. 62 Strategy framework

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のT細胞療法市場2021-2028:モダリティ別、治療別(CAR T細胞、腫瘍浸潤リンパ球)、疾患別(血液悪性腫瘍、固形腫瘍)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆